Multiple Myeloma in Relapse Withdrawn Phase 1 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02658396GO-203-2C + Bortezomib For Relapsed Or Refractory MMTreatment